Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy
Science Translational Medicine · 23.09.2026 · 18 (868)
DOI: 10.1126/scitranslmed.aed8692 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, erschienen am 23.09.2026. Verfasst von Natalie Hudson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, Ireland. Hauptthemen laut MEDLINE: Diabetic Retinopathy. Die Arbeit nennt 45 Literaturangaben. Gefördert von: H2020 European Research Council, European Research Council.
Abstract (Originalsprache)
Nonproliferative diabetic retinopathy (NPDR) is a serious and vision-threatening manifestation of diabetic eye disease. Most patients with diabetic eye disease have NPDR. Intravitreal vascular endothelial growth factor (VEGF)–neutralizing agents are able to suppress increased vascular leakage caused by poor glycemic control and are fundamental in controlling progression to vision loss. However, despite the efficacy of such treatments, the invasive nature and short interval between injections have not yielded widespread adoption in patients with NPDR. Here, we describe the effect of an orally available medication, danegaptide, in regulating retinal vascular permeability in preclinical animal models of disease and report safety and early efficacy data from an early-stage phase 1b clinical trial in patients with NPDR and mild center-involved macular edema. As an orally available gap junction modifier, danegaptide improved inner blood-retina barrier (iBRB) function through a direct connexin-43 mechanism and by working as a functional antagonist of VEGF in human retinal microvascular endothelial cells. Bulk RNA sequencing showed that danegaptide attenuated the VEGF-induced suppression of TNFSF15 , an endogenous antagonist of VEGF activity in human retinal microvascular endothelial cells. In addition, targeted suppression of TNFSF15 using small interfering RNA or inhibition of its activity using a neutralizing antibody prevented VEGF-induced permeability in vitro and neovascular lesion development in vivo. No serious adverse events related to oral danegaptide were found in an early-stage phase 1b clinical trial in 24 patients with NPDR and mild center-involved macular edema. These findings support larger clinical trials to test efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, Ireland.
- FutureNeuro Research Ireland Centre, Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, Ireland.
- Breye Therapeutics, 2970 Hørsholm, Denmark.
ORCID-Profile: Natalie Hudson, Gergő Porkoláb, Jeffrey O'Callaghan, Nicole Hanley, Ulrik Mouritzen, Peter Adamson, Matthew Campbell
Förderung
- H2020 European Research Council
- European Research Council
Zitieren
APA
Hudson, N., Porkoláb, G., O'Callaghan, J., Hanley, N., Baccouche, B., Varró, M., Mouritzen, U., Lind, B. E., Adamson, P., & Campbell, M. (2026). Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy. Science Translational Medicine, 18(868). https://doi.org/10.1126/scitranslmed.aed8692
Vancouver
Hudson N, Porkoláb G, O'Callaghan J, Hanley N, Baccouche B, Varró M, et al. Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy. Science Translational Medicine. 2026;18(868). doi:10.1126/scitranslmed.aed8692
BibTeX
@article{Hudson2026,
author = {Hudson, Natalie and Porkoláb, Gergő and O'Callaghan, Jeffrey and Hanley, Nicole and Baccouche, Basma and Varró, Márk and Mouritzen, Ulrik and Lind, Benedikte El-Bandak and Adamson, Peter and Campbell, Matthew},
title = {Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {868},
doi = {10.1126/scitranslmed.aed8692}
}
EUVIMED